Synapse - Works

Results (4640)

A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of patients in CheckMate 649: Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC)

Meeting Abstract

Sugarman, R.; Botteman, M.; Rusibamayila, N.; Nguyen, H.; Lin, D.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Number needed to treat (NNT) analysis of patients in CheckMate 649 (CM 649): Nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJ/EAC)

Meeting Abstract

Sugarman, R.; Nunna, S.; Betts, K. A.; Nie, X.; Nguyen, H.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104

Meeting Abstract

Soares, H. P.; Guthrie, K. A.; Ahmad, S. A.; Washington, M. K.; Ramnaraign, B. H.; Raj, N. P.; Seigel, C.; Bellasea, S.; Chiorean, E. G.; Dasari, A.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

The immune impact of PI3K-AKT pathway inhibition in colorectal cancer

Meeting Abstract

Nusrat, M.; Syed, M. A.; Katkhuda, R.; Parra, E. R.; Wistuba, I. I.; Kong, P.; Koehne, A.; Dasari, A.; Overman, M. J.; Menter, D.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Distinct differences in genomic profile of gastric and gastroesophageal junction adenocarcinoma

Meeting Abstract

Nakauchi, M.; Walch, H. S.; Chatila, W. K.; Tran, T.; Vos, E. L.; Sihag, S.; Tang, L. H.; Coit, D. G.; Stadler, Z. K.; Janjigian, Y. Y.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Salvage ablative radiation therapy for loco-regionally recurrent pancreatic ductal adenocarcinoma following surgical resection

Meeting Abstract

Ng, V.; Zinovoy, M.; Hajj, C.; Romesser, P. B.; Wu, A. J. C.; Cuaron, J. J.; Jarnagin, W. R.; O'Reilly, E. M.; Crane, C. H.; Reyngold, M.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Early-onset well differentiated pancreatic neuroendocrine tumors: Clinical presentation, pathologic features, and oncological outcomes

Meeting Abstract

Pulvirenti, A.; Hauser, H.; Le, T.; McIntyre, C. A.; Reidy, D. L.; Wei, A. C. C.; Raj, N. P.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348)

Meeting Abstract

Lim, H. Y.; Heo, J.; Kim, T. Y.; Tai, W. M. D.; Kang, Y. K.; Lau, G.; Kudo, M.; Tak, W. Y.; Watras, M.; Ali, S. K.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Feasibility and utility of synthetic control arms derived from real-world data to support clinical development

Meeting Abstract

Lyman, J. P.; Doucette, A.; Zheng-Lin, B.; Cabanski, C. R.; Maloy, M. A.; Bayless, N. L.; Xu, J.; Smith, W.; Karakunnel, J. J.; Fairchild, J. P.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer

Meeting Abstract

Lumish, M. A.; Cohen, J. L.; Stadler, Z. K.; Weiss, J. A.; Lamendola-Essel, M. F.; Yaeger, R.; Segal, N. H.; El Dika, I. H.; Saltz, L. B.; Shcherba, M.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save